Clinical trial · Observational
Anticoagulation in Patients With Venous Thromboembolism and Cancer
VICTORIE (VTE IN CANCER - TREATMENT, OUTCOMES AND RESOURCE USE IN EUROPE)
NCT04618913CI-TRIAL-00119220VICTORIEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Embolism | — | UNRESOLVED | — |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apixaban | Drug | — | UNRESOLVED |
| Dabigatran | Drug | — | UNRESOLVED |
| Edoxaban | Drug | — | UNRESOLVED |
| LMWH | Drug | — | UNRESOLVED |
| Rivaroxaban | Drug | — | UNRESOLVED |
| VKA | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- VTE and active cancer
- description
- VTE and active cancer
- interventionNames
- Drug: Apixaban
- Drug: Rivaroxaban
- Drug: Edoxaban
- Drug: Dabigatran
- Drug: VKA
- Drug: LMWH
- label
- VTE and history of cancer
- description
- VTE and history of cancer
- interventionNames
- Drug: Apixaban
- Drug: Rivaroxaban
- Drug: Edoxaban
- Drug: Dabigatran
- Drug: VKA
- Drug: LMWH
Primary outcomes (1)
- measure
- Recurrence of Thromboembolism
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * A VTE diagnosis * Active cancer or history of cancer * Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH * Age ≥ 18 years at the date of index VTE (Venous thromboembolic) Exclusion Criteria: * Prior VTE diagnosis * Diagnosis of prior atrial fibrillation * Inferior Vena Cava (IVC) filter * Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed. * Pregnancy * More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date. * Patients with less than one day of follow up
References
Publications (0)
Data not yet available
No reference posted for this study.